Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in doctors’ offices.  O | Cancer ...

In patients with type 2 diabetes, GLP-1 use was not associated with higher risks for most serious gastrointestinal or ...

Adults with obesity who reported more intense tastes while receiving semaglutide or tirzepatide had a higher likelihood for ...

Novo Nordisk, the company that owns both Wegovy and Ozempic, will be selling the medicine at nearly half the out-of-pocket ...

GLP-1 RA Effects Beyond Glycaemic Control A RECENT network meta-analysis suggests that GLP-1 receptor agonists (GLP-1 RAs) ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

Surgery reduces the risks of death, heart disease, kidney failure, and eye damage more effectively than GLP-1 medicines. A major study conducted at Cleveland Clinic found that individuals with obesity ...